| German Center for Neurodegenerative Diseases (DZNE) | |
|---|---|
| Location | Bonn, Germany (Headquarters) |
| Type | National Research Center |
| Founded | 2009 |
| Website | www.dzne.de |
| Affiliation | German Centers for Health Research (DZG) |
| Staff | ~1,000 employees |
| Sites | 10 across Germany |
The German Center for Neurodegenerative Diseases (Deutsches Zentrum für Neurodegenerative Erkrankungen, DZNE) is Germany's national research center dedicated to understanding the mechanisms of neurodegenerative diseases and developing novel therapeutic approaches. Established in 2009 as part of the German Centers for Health Research (DZG), DZNE brings together researchers from across Germany to tackle Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative disorders[1][2].
DZNE operates as a nationwide network with ten sites across Germany, including major universities and research institutions in Bonn (headquarters), Berlin, Dresden, Göttingen, Magdeburg, Munich, Rostock, Tübingen, Witten, and Ulm. This distributed structure allows the center to leverage expertise from diverse institutions while maintaining centralized coordination. With approximately 1,000 employees, DZNE represents one of the largest coordinated neurodegeneration research efforts in Europe[3].
DZNE was established in 2009 by the German Federal Ministry of Education and Research (BMBF) as part of a national strategy to address the growing burden of neurodegenerative diseases. The center was modeled on the successful German Cancer Research Center (DKFZ) and represents Germany's largest coordinated effort in neurodegeneration research. The establishment was part of a broader initiative creating six German Centers for Health Research to address major diseases including cancer, cardiovascular disease, diabetes, infectious diseases, and neurodegeneration[2:1].
Since its founding, DZNE has grown to include over 1,000 employees across its ten sites, making it one of the largest neurodegeneration research centers in Europe. The center has established extensive international collaborations and has become a major player in global Alzheimer's and Parkinson's disease research. Key milestones include:
DZNE researchers investigate all aspects of Alzheimer's disease[4][5][6]:
Research programs include[9][10][11]:
| Site | Focus Areas |
|---|---|
| Bonn (HQ) | Overall coordination, clinical research, data science |
| Berlin | Clinical trials, epidemiology, prevention research |
| Dresden | Protein aggregation, biophysics, structural biology |
| Göttingen | Systems neuroscience, electrophysiology |
| Magdeburg | Computational neuroscience, AI/machine learning |
| Munich | Clinical research, imaging, biomarker development |
| Rostock | Population studies, epidemiology, prevention |
| Tübingen | Stem cell models, iPSC technology |
| Witten | Prevention research, care research |
| Ulm | Neurobiology, molecular mechanisms |
A nationwide network of researchers collaborating on:
German Parkinson's disease registry connecting:
Centralized infrastructure providing:
| Researcher | Site | Specialization |
|---|---|---|
| Prof. Michael Ewers | Berlin | Biomarkers, neuroimaging |
| Prof. Andreas Beyer | Bonn | Data science, AI |
| Prof. Jochen Klucken | Bonn | Alpha-synuclein biology |
| Prof. Thomas Gasser | Tübingen | PD genetics |
| Prof. Manuel Zimmer | Göttingen | Systems neuroscience |
| Prof. Peter Nestor | Magdeburg | Computational modeling |
| Prof. Anja Schneider | Bonn | Clinical research |
DZNE offers comprehensive training opportunities:
DZNE Annual Report. (2023) German Center for Neurodegenerative Diseases. 2023. ↩︎
German Federal Ministry of Education and Research. Launch of German Centers for Health Research. 2009. ↩︎ ↩︎
Haass C, Selkoe D. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007. ↩︎
Selkoe DJ. Alzheimer disease and AD pathogenesis. Handb Clin Neurol. 2019. ↩︎
Haass C, et al. Alzheimer disease: from basic science to clinical development. Nat Med. 2022. ↩︎
De Strooper B, Karran E. The cellular phase of Alzheimer disease. Cell. 2018. ↩︎
Blennow K, et al. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2015. ↩︎
Heneka MT, et al. Neuroinflammation in Alzheimer disease. Nat Rev Neurol. 2015. ↩︎
Kalia LV, Lang AE. Parkinson disease. Lancet. 2015. ↩︎
Spillantini MG, et al. Alpha-synuclein in Lewy bodies. Nature. 2000. ↩︎
Braak H, et al. Staging of brain pathology related to sporadic Parkinson disease. Neurobiol Aging. 2003. ↩︎
Gandhi S, et al. Alpha-synuclein and mitochondrial dysfunction. J Parkinsons Dis. 2022. ↩︎